T28. A COMPARISON BETWEEN OLANZAPINE CONTINUATION AND AMISULPRIDE COMBINATION IN ACUTE SCHIZOPHRENIA PATIENTS SHOWING EARLY NON-RESPONSE TO OLANZAPINE: 4-WEEKS, RANDOMIZED, RATER-BLINDED PILOT STUDY

Assessment of strategies for switching patients from olanzapine to risperidone: A randomized, open-label, rater-blinded study

BACKGROUND In clinical practice, physicians often need to change the antipsychotic medications they give to patients because of an inadequate response or the presence of unacceptable or unsafe side effects. However, there is a lack of consensus in the field as to the optimal switching strategy for antipsychotics, especially with regards to the speed at which the dose of the previous antipsychot...

Aripirazole-olanzapine combination for treatment of schizophrenia.

Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.

INTRODUCTION Agitation is a major problem in acute schizophrenia. Only a few studies have tested antipsychotic agents in severely agitated patients, mainly because of legal issues. Furthermore, most studies were limited to the first 24 hours. We aimed to investigate the efficacy of oral haloperidol, risperidone, and olanzapine in reducing psychotic agitation in severely agitated patients with s...

memantine enhances the effect of olanzapine in patients with schizophrenia: a randomized, placebo-controlled study

glutamate dysregulation may be involved in the neuropathology of schizophrenia. memantine, a drug approved by the fda for the treatment of moderate to severe alzheimer's disease, acts as a partial uncompetitive nmda receptor antagonist. the aim of this study was to examine the efficacy of memantine as an adjunctive treatment to olanzapine in patients with schizophrenia. in this double-blind, pl...

Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia

PURPOSE We examined whether augmentation with olanzapine would be superior to switching to olanzapine among early non-responders (ENRs) to risperidone, and whether augmentation with risperidone would be superior to switching to risperidone among ENRs to olanzapine. We performed a rater-blinded, randomized clinical trial at psychiatric emergency sites. Eligible patients were newly admitted patie...